Enzyme Kinetics

Definition

• Enzyme kinetics is the quantitative study of how reaction velocity depends on substrate concentration, enzyme quantity, and the presence of inhibitors or activators. The Michaelis-Menten framework reduces this to two constants — Km, an inverse index of substrate affinity, and Vmax, a measure of total catalytic capacity.
• Because enzymes are saturable, the same pathway can behave in two entirely different regimens: proportional (first-order) clearance at low substrate load and fixed-capacity (zero-order) clearance once active sites are occupied. Nearly every clinical application flows from that single distinction.

Why it matters clinically

• Rational pharmacology: most small-molecule drugs were designed as reversible inhibitors of a specific enzyme, and the kinetic signature predicts whether the effect can be outcompeted by substrate. This underlies statin therapy in the ACC/AHA 2018 Cholesterol Guideline, sulfonamide antimicrobials, and antidotes such as fomepizole.
• Toxicology and dosing safety: saturation kinetics explains disproportionate serum-level rises with agents like phenytoin and the shift to hepatotoxic metabolite generation in acetaminophen overdose, where AASLD acute liver failure guidance treats N-acetylcysteine as standard.
• Inborn errors and pharmacogenetics: point mutations that raise Km or lower Vmax produce disease without abolishing the enzyme, and cofactor supplementation can sometimes restore flux.

Epidemiology worth recalling

• Glucose-6-phosphate dehydrogenase deficiency is the most common enzymopathy in the world, affecting hundreds of millions, X-linked, and concentrated in populations of African, Mediterranean, Middle Eastern, and Southeast Asian ancestry.
• NAT2 slow-acetylator status is present in roughly half of US White and Black patients and a smaller fraction of East Asian patients, raising isoniazid, hydralazine, and procainamide exposure.
• Monogenic diabetes accounts for only a small percentage of all diabetes, but GCK-MODY — a Km-shifting glucokinase mutation — is among its most common forms; the ADA Standards of Care recommends genetic confirmation, since these patients often need no pharmacotherapy.
• CPIC publishes freely available gene-drug guidelines (for example CYP2C19 and clopidogrel, TPMT/NUDT15 and thiopurines) that translate inherited kinetic variation into dosing.

The core reaction scheme

• E + S ⇌ ES → E + P: substrate binds reversibly to the active site (k₁, k₋₁), then the ES complex is converted to product at the catalytic rate constant k꜀ₐₜ. Enzymes lower activation energy; they do not change ΔG or the position of equilibrium.
• Steady-state (Briggs-Haldane) assumption: [ES] is constant because formation and breakdown are balanced. This is the assumption behind the Michaelis-Menten equation and is why kinetics are measured at initial velocity, before product accumulates.
• Km = (k₋₁ + k꜀ₐₜ)/k₁: when k꜀ₐₜ is small, Km approximates the dissociation constant, so it functions as an inverse index of affinity. Km is an intrinsic property of the enzyme-substrate pair and is independent of enzyme concentration.
• Vmax = k꜀ₐₜ × [E]total: Vmax is directly proportional to the amount of enzyme present. Anything that changes enzyme quantity — gene induction, hepatocyte loss, irreversible inactivation — changes Vmax.
• Catalytic efficiency = k꜀ₐₜ/Km, the parameter used to compare isozymes.

Order of the reaction

• At [S] ≪ Km, velocity rises nearly linearly with substrate: first-order, and a constant fraction is metabolized per unit time (this is the domain of most therapeutic drug dosing).
• At [S] ≫ Km, all active sites are occupied: zero-order, and a constant amount is metabolized per unit time regardless of how much more substrate is added.

Regulation points examiners ask about

• Allosteric effectors shift apparent Km (K-type) or Vmax (V-type); cooperative multi-subunit enzymes give a sigmoid rather than hyperbolic curve (as with hemoglobin's oxygen binding).
• Covalent modification — phosphorylation/dephosphorylation by kinases and phosphatases under hormonal control.
• Zymogen activation by proteolytic cleavage (trypsinogen, clotting factors, caspases).
• Transcriptional induction/repression, which alters [E]total and therefore Vmax over hours to days.
• Isozyme design by Km: hexokinase has a low Km/low Vmax and is product-inhibited by glucose-6-phosphate, whereas hepatic glucokinase has a high Km/high Vmax and is regulated by the glucokinase regulatory protein — so the liver only takes up glucose in bulk after a meal.
• Rate-limiting enzymes are typically the committed, allosterically regulated step (phosphofructokinase-1 in glycolysis, HMG-CoA reductase in cholesterol synthesis, ALA synthase in heme synthesis).

Drugs designed as competitive inhibitors (↑ Km, Vmax preserved)

• Statins (atorvastatin): substrate analogs of HMG-CoA at HMG-CoA reductase; the ACC/AHA 2018 Cholesterol Guideline makes moderate- to high-intensity statin therapy the foundation of ASCVD risk reduction.
• Methotrexate: folate analog competing at dihydrofolate reductase; leucovorin rescue works precisely because it floods the pathway downstream, and high-dose regimens exploit reversibility.
• Fomepizole: competes with methanol/ethylene glycol at alcohol dehydrogenase, preventing formic acid and oxalate generation. Fomepizole plus hemodialysis is the standard antidotal approach in American poison-center practice; ethanol is an inferior competitive substitute.
• Sulfonamides: PABA analogs at dihydropteroate synthase — the classic mechanism-based competitive antimicrobial.

Irreversible or noncompetitive inactivation (↓ Vmax, not overcome by substrate)

• Aspirin acetylates COX-1/COX-2; recovery requires new enzyme synthesis, which is why platelet effects last the platelet lifespan.
• Organophosphates phosphorylate acetylcholinesterase, producing DUMBBELSS cholinergic crisis; management is atropine for muscarinic effects plus pralidoxime to regenerate enzyme before aging.
• Cyanide at cytochrome c oxidase and carbon monoxide at complex IV/hemoglobin produce lactic acidosis with normal or elevated venous oxygen saturation.
• Lead inhibits ALA dehydratase and ferrochelatase → microcytic anemia with basophilic stippling and elevated protoporphyrin.

Saturation (zero-order) toxicity

• Phenytoin: small dose increments cause disproportionate level rises once hepatic hydroxylation saturates → nystagmus, ataxia, and eventually gingival hyperplasia with chronic use.
• Acetaminophen and salicylates shift to zero-order in overdose. For acetaminophen, the single best next step is a 4-hour-or-later serum level plotted on the Rumack-Matthew nomogram and N-acetylcysteine, which replenishes glutathione for NAPQI conjugation; AASLD acute liver failure guidance treats N-acetylcysteine as the standard antidote.

Mutations that change kinetic constants

• Glucokinase (GCK) mutations raise the glucose threshold for insulin secretion → mild, stable fasting hyperglycemia (MODY), which the ADA Standards of Care notes is often managed without insulin once monogenic diabetes is confirmed genetically.
• Cofactor-responsive inborn errors: some cystathionine β-synthase mutants have reduced affinity for pyridoxal phosphate, so pharmacologic pyridoxine restores flux in pyridoxine-responsive homocystinuria.

• Km is a concentration, not a rate: it is the [S] giving ½ Vmax. Low Km = high affinity. Km does not change when you add or remove enzyme; Vmax does, because Vmax = k꜀ₐₜ × [E]total.
• Competitive inhibition: ↑ apparent Km, unchanged Vmax, fully overcome by raising [S]. On Lineweaver-Burk the lines share the y-intercept (1/Vmax) and the slope steepens.
• Pure noncompetitive inhibition: ↓ Vmax with Km unchanged (the inhibitor binds E and ES equally at an allosteric site), giving lines that share the x-intercept (−1/Km). When an inhibitor prefers free enzyme, the pattern becomes mixed inhibition and Km rises as well — this is the nuance behind conflicting textbook descriptions.
• Uncompetitive inhibition (binds ES only) lowers Km and Vmax proportionally and is the classic source of parallel Lineweaver-Burk lines — the most common distractor is to assign parallel lines to competitive inhibition.
• Zero-order buzzwords: phenytoin, ethanol, aspirin (at toxic levels). A stem describing a disproportionate rise in drug level after a small dose increase is testing saturation kinetics, not renal failure.
• Hexokinase vs glucokinase is the single most tested Km comparison: low Km/low Vmax and G6P inhibition in muscle versus high Km/high Vmax with GKRP regulation in liver; GCK mutations produce a right-shifted glucose sensor and MODY.
• Best next step in acetaminophen overdose is a 4-hour serum acetaminophen level applied to the Rumack-Matthew nomogram, with N-acetylcysteine given without waiting when presentation is late or the history is high-risk.
• Enzymes do not change ΔG or Keq — they lower activation energy and accelerate both directions equally. Any answer choice claiming an enzyme makes an unfavorable reaction favorable is wrong.

• Michaelis-Menten equation (V = Vmax[S]/Km + [S]) describes enzyme kinetics under steady-state conditions
• Km = substrate concentration at ½ Vmax; lower Km = higher affinity; Vmax = maximum velocity at saturation
• Lineweaver-Burk plot (1/V vs 1/[S]) linearizes Michaelis-Menten curve; used to identify inhibition types
• Enzymes follow zero-order kinetics at high substrate (Vmax-limited) and first-order kinetics at low substrate (Km-limited)
• Clinical significance: Drug metabolism and toxin elimination follow Michaelis-Menten kinetics

• Confusing Km with affinity direction: Lower Km = HIGHER affinity (tighter binding), not lower affinity
• Mistaking inhibition types on L-B plots: Competitive = parallel lines (↑ Km); noncompetitive = lines intersect on y-axis (↓ Vmax); uncompetitive = parallel lines with different y-intercepts
• Assuming all drug metabolism is first-order: At therapeutic doses, yes; but toxins/overdoses often shift to zero-order (saturation), explaining nonlinear toxicity

• Drug dosing adjustments in renal/hepatic disease (reduced Vmax)
• Drug interactions via competitive inhibition (e.g., warfarin + NSAIDs)
• Overdose management: N-acetylcysteine for acetaminophen restores Phase II capacity; hemodialysis for zero-order kinetics toxins (ethylene glycol, methanol)